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ASSESSMENT OF DISCLOSURE IN
EUROPEAN PRODRUG PATENT CLAIMS
MARI MINN PHD, LLM
ABSTRACT
The article discusses the concept of disclosure in European patent
applications involving prodrugs and active metabolites thereof. The article
begins with an introduction to the scientific aspects of prodrug design to
understand their meaning and difference from common drugs. It is followed
by legal analysis discussing the notion of “disclosure” as an element of
assessing novelty and inventive step. The article argues that the “disclosure”
should be broken off into scientific disclosure affecting novelty criteria and
disclosure as an element of enablement to judge the inventive step. The
arguments of the article is based on the ruling of the United Kingdom (“UK”)
landmark case Merrell Dow Pharmaceuticals v. Norton Limited and Penn
Pharmaceuticals that has dealt with the assessment of novelty criteria by
separating scientific disclosure from disclosure through use. As analyzed in
the article, novelty assessment based on the disclosure doctrine may destroy
the novelty criteria because of scientific “gaps” that may exist in the parent
drug leading to potential infringement by the second-generation claim. The
article also discusses the applicability of the inventive step requirement by
analyzing relevant case law concluding that differently from the novelty
criteria, the later should be applied differently considering explicitly
available information about prior art or in other words, enablement of
disclosure. Therefore, the notion and extent of the disclosure have a versatile
impact on the assessment of the patentability criteria depending on whether
it targets the novelty or the inventive step requirement.
I.

THE SCIENCE BEHIND PRODRUGS

Many of the most common medicines are not effective in treating a
large number of patients because of the genetic makeup that is responsible
for determining how a specific drug reacts in a human body. The common
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drug research involving a vast quantity of drug molecules cannot provide
targeted solutions that can overcome physiochemical, biological or other
barriers in drug efficiency and/or toxicity. Because of the genetic makeup,
some people metabolize drugs slowly leading to toxic accumulation of the
drug or some people metabolize drugs too quickly which may result in
inefficiency of the drug action in the human body. When a new chemical
entity shows barriers or limitations about its utility, it cannot be developed
further into a therapeutic agent. 1 During the research phase, the most
common problem related to the development of new drugs concerns
solubility problems. Even with the use of current computational “filters” to
minimize this problem, 2 compounds that are active in vitro may lack
adequate pharmacokinetic properties and/or may be difficult to formulate. 3
Striving to improve the properties of a given drug and overcome the negative
side effects of an existing drug, prodrugs have become valuable tools for
modern drug development. A prodrug is a pharmacologically inactive
substance4 that must go through a chemical or enzymatic transformation to
become effective inside the body. Thus, the therapeutic rationale behind
prodrugs is to enhance the properties of the parent drug once metabolized in
the body.
According to Huttunen, prodrug strategy has been used to increase the
selectivity of drugs for their intended target. 5 These types of drugs are
striving to offer safer and better-targeted treatment options in modern
medicine. Metabolites6 that are closely related to prodrugs are eventually
formed as a result of a natural biochemical process of degrading and
eliminating compounds. Therefore, to differentiate between prodrugs and
metabolites, it can be said that if the pharmacological effect of a medication
is due to the transformation of a drug into a metabolite, the medication may
1. See generally Valentino J. Stella, Prodrugs: Some Thoughts and Current Issues, 99 J. PHARM.
SCI. 4755 (2010).
2. Jarkko Rautio et al., Prodrugs: Design and Clinical Applications, 7 NAT. REV. DRUG DISCOV.
255, 255 (2008).
3. A study conducted with the top 200 oral drug products in Japan, Great Britain, United States,
and Spain revealed that approximately 37 percent of drugs had solubilities of less than 0.1 mg/mL See
Toshihide Takagi et al., A Provisional Biopharmaceutical lassification of the Top 200 Oral Drug
Products in the United States, Great Britain, Spain, and Japan, 3 MOL. PHARM. 631, 635 (2006).
4. The prodrug itself is often biologically inactive but may also possess biological activity—
serving as a drug itself.
5. Kristiina M. Huttunen et al., Prodrugs – from Serendipity to Rational Design, 63
PHARMACOLOGICAL REVIEWS, 750, 751 (2011).
6. Edward D. Harris, Biochemical Facts behind the Definition and Properties of Metabolites,
https://www.fda.gov/ohrms/dockets/ac/03/briefing/3942b1_08_Harris%20Paper.pdf (last visited Mar.
18, 2019).
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be called “a drug” and an “active metabolite”.7 If, on the other hand, the said
effect is due to the release of the drug from a larger chemical entity, then the
medication is called “drug” and “prodrug.”
Prodrugs can masked forms of active drugs that are designed to be
activated after an enzymatic or chemical reaction once they are into the
body.8 Considering that during the R&D process of the parent drug it is not
always possible to foresee all its properties, prodrugs as second-generation
products seek to modify some of the shortcomings of the parent drug
pertaining to absorption, distribution or metabolism. The active metabolite
that is eventually responsible for the drug’s in vivo pharmacological effect
differs structurally from the existing prodrug that is administered to the
patient. 9 A small structural modification, however, may result in major
differences in biological activity.10 Thus, second generation products can not
only serve as a more efficient treatment option but also provide a high return
on investment for a pharmaceutical company. The development of medicine
using an active ingredient, the safety, and efficacy of which have already
been established, is normally less time consuming, less expensive, and less
risky than using a compound about which little is known.11
From the intellectual property law perspective, it is important to
consider that prodrugs are inactive derivatives of drug molecules that were
already contained in the parent drug that is developed to overcome
therapeutic barriers in drug delivery. It means that in most cases prodrugs
are simple chemical derivatives that are only one or two chemical or
enzymatic steps away from the active parent drug as it incorporates an active
molecular entity within another molecular structure. To illustrate this,
according to a study, 49 percent of all prodrugs are targeted at the formation
of esters, which means that they are structurally like the parent drug.12 Some
of the recently approved prodrugs include a very controversial Sofosbuvir
that is challenged by the European Patent Office (“EPO”).
7. HYEWON AHN, SECOND GENERATION PATENTS IN PHARMACEUTICAL INNOVATION, 19 MIPLC
STUDIES 47-49 (2014).
8. See generally, Peter Ettmayer et al., Lessons Learned From Marketed and Investigational
Prodrugs, 47 J. MED. CHEM. 2393, 2394 (2004); See generally Valentino J. Stella, Prodrugs: Some
thoughts and current issues, 99 J. PHARM. SCI., 4755, (2010).
9. See generally Ralph Minderop et al., Prodrugs and Metabolites – In the Twilight Zone of
Patentability?, 2 IP IN THE LIFE SCIENCES INDUSTRIES 9, (2013).
10. Case T 0939/92, Triazoles (1995).
11. Nat’l Inst. for Health Care Mgmt., Changing Patterns of Pharmaceutical Innovation (2002),
http://nihcm.org/pdf/innovations.pdf.
12. Jarkko Rautio et al., Prodrugs: Design and Clinical Applications, 7 NATURE REVIEWS 255, 256
(2008).
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From a legal point of view, prodrugs may offer a valuable opportunity
to extend the life cycle of the parent drug. It is estimated that prodrugs
account for 5-10 percent of the overall global drug market.13 Most patents
targeting prodrugs are related to oncological research although the range of
truly innovative drugs is, according to the same study, not more than 5-10
percent, which suggests that many of these patents are small improvements
or adjustments of currently existing drugs.
Considering that prodrugs are mainly applied for as secondary patents,
they can add 6.3 additional years to the product life cycle.14 According to
Kapczynski, depending on the category of independent secondary patents,
formulation patents when applied as secondary independent claims add
approximately 6.5 years of patent life, secondary independent claims for
salts, polymorphs, esters, etc., add 6.3 years and independently claimed a
method of use claims add 7.4 years. 15 According to the European
Pharmaceutical Sector Inquiry executed by the European Commission,
applications on second generation patents for bestselling medicines is a
common strategy to evergreen product lifecycle. The number of second
generation patents rises significantly at the end of basic patents. 16 The
Inquiry found that in 40 percent of cases first-generation patents are followed
by second-generation patents and the average time before the launching of
the second-generation patent was estimated to take place 1.5 years before the
expiry of the basic patent. 17 Kapczynski has observed that independent
secondary patents are not obtained randomly but rather the propensity to
obtain secondary patents increases after successful sales suggesting they
reflect deliberate attempts by branded firms to lengthen their monopoly for
more lucrative drugs.18 The EC Pharmaceutical Inquiry Report revealed a
primary to a secondary patent ratio of 1:7 meaning that the number of
secondary patents is much higher in comparison to initial patents obtained in

13. Jarkko Rautio et al., Prodrugs – Recent Approvals and a Glimpse of the Pipeline, 109 EUR. J.
PHARMACEUTICAL SCI. 109, 146–61 (2017).
14. Amy Kapczynski et al., Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis
of
“‘Secondary”
Pharmaceutical
Patents,
7
PLOS
ONE
49470(2012),
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049470.
15. Id.
16. EUROPEAN
COMM’N,
PHARMACEUTICAL
SECTOR
INQUIRY
REPORT
(2009),
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf.
17. Id.
18. Amy Kapczynski et al., Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis
of
“‘Secondary”
Pharmaceutical
Patents,
7
PLOS
ONE
49470
(2012),
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049470.
.
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the beginning of drug lifecycle. 19 The interesting aspect of secondgeneration patents is that most studies analyze and estimate the effects of
patenting strategies based on calculations related to the filing date of firstgeneration patents20 thus, ignoring the potential effects of second-generation
filings to the patent portfolio lifetime. If secondary patents are frequently
obtained later in the invention cycle then chemical compound patents, this
will underestimate patent life, perhaps substantially.21
Considering that a prodrug is structurally similar to its parent drug, two
questions arise regarding patentability standards of these drugs. The first
question that arises is the extent of disclosure or free use after the expiry of
the parent drug in case a prodrug is claimed later during the life cycle
process. The second question, connected to the first, is the validity of the
prodrug patent in the light of fulfillment of the novelty and inventive step
requirements. This article provides insight into these problems in the
following sections and discusses the normative uncertainties by analyzing
the most relevant case law.
II. THE IMPACT OF DISCLOSURE IN FIRST-GENERATION CLAIMS TO
PRODRUG PATENT APPLICATIONS

Based on the data retrieved from the European Patent Register, it seems
that most patents for prodrugs are claimed as second-generation patents.
There can be several reasons that could explain it. It is possible that, at the
time of filing the first-generation claim, potential shortcomings of the parent
drug were not known which later caused the filing of the second-generation
claim. It is also possible that the shortcomings in the first-generation drug
were actually known already during the first filing, but the second-generation
patent was later used as part of product life cycle management.
It is a fundamental principle of patent practices that after the expiry of
the basic patent the subject matter falls in the public domain meaning that it
becomes accessible to anyone without having to worry about the
infringement. When the subject matter falls in public domain, no further
patent should be granted to the same subject matter; otherwise it would lead
to double patenting. If anyone attempted to craft a patent application
covering the earlier subject matter, under the assumption that the earlier
19. EUROPEAN
COMM’N,
PHARMACEUTICAL
SECTOR
INQUIRY
REPORT
(2009),
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf.
20. See generally Henry G. Grabowski & John M. Vernon, Effective Patent Life in
Pharmaceuticals, 19 INT’L. J. TECH. MGMT. 98 (2000).
21. See generally C. Scott Hemphill & Bhaven N. Sampat, When Do Generics Challenge Drug
Patents?, 8 J. EMPIRICAL LEGAL STUD. 613 (2011).
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disclosure was complete and enabling enough, it would destroy the novelty
and/or the inventive step requirement. However, considering that prodrug
applications are line extensions of the parent drug, there are a few aspects to
consider.
For a new claim to be patent eligible, a complete and enabling
disclosure is required which is then assessed from the practical point of view.
This means that the disclosure of the claim should be complete enough to
enable a person skilled in the art to perform the invention without undue
burden. Article 84 of the European Patent Convention (“EPC”) states the
following: “The claims shall define the matter for which protection is sought.
They shall be clear and concise and be supported by the description.”22 In
its case law, the EPO has clarified that Article 84 of the EPC requires that
the claims define the subject matter for which patent protection is sought. It
signifies that the disclosure should specify all the essential features needed
to define the invention and that the meaning of these features should be clear
for the person skilled in the art from the wording of the claim.23 Based on the
EPO Board’s interpretation in case T 409/91, the underlying purpose of
Article 83, directed to the disclosure of the invention, is the same as is stated
in Article 84 of the EPC, Namely, to secure the grant of the proper breadth
of patent exclusivity that can be justified by the technical contribution to the
art. 24 The well-established jurisprudence of the EPO in respect to the
interpretation of Article 84 of the EPC, requires that to be patentable, an
independent claim must recite all the essential features which are necessary
for clearly and completely defining a particular invention.25 Therefore, the
claim should define the subject matter by reference to all its essential
technical features. 26 Although the disclosure must contain sufficient
information for the skilled person to perform the invention, there is no
requirement that the inventor should have full scientific understanding
behind the invention. In many situations, it is not possible to add the full
disclosure in the patent application, especially in the case of biotechnological
patents and pharmaceutical patents, as it is not possible to delimit the
invention. From the legal point, the reason why it is relevant to differentiate
between the scientific disclosure and practical (enabling) disclosure is that it

22. See Convention on the Grant of European Patents art. 84, Oct. 5, 1973, 1065 U.N.T.S. 199
[hereinafter European Patent Convention].
23. Case G 0001/04, Diagnostic Methods, OJ EPO 2006, ¶ 6.2.4.
24. Case T 0409/91, Fuel Oils, OJ EPO 1994, 3.5.
25. Case G 0001/04, Diagnostic Methods, OJ EPO 2006, ¶ 6.2.4.
26. Case G 0001/04, Diagnostic Methods, OJ EPO 2006, ¶ 6.2..
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defines the extent of the subject matter for which protection is sought and
how it reflects the evaluation of novelty and the inventive step requirements.
It is especially relevant for patents involving prodrugs as a small piece of
scientific information in the disclosure to determine the perspective for
patentability.
According to Article 83 of the EPC, the claim must also contain
sufficient technical disclosure of the solution to the problem. 27 EPO
Guidelines for Examination clarify that a detailed description of at least one
way of carrying out the invention must be given. Therefore, the description
should disclose any essential feature for carrying out the invention by the
person skilled. When the first-generation patent is claimed for the parent
drug, the disclosure should include a number of examples, alternative
embodiments or variations of the subject matter extending over the area
protected by the claim.28
In its case T-0409/91 the EPO Boards of Appeal has held that “The
essential features of the invention, which must be used for defining the
matter for which protection is sought, in accordance with Art. 84 EPC in
combination with Rule 29(1) and (3), are all those technical features which
are necessary to define an invention which is patentable under the EPC,
including any feature which is necessary to define matter which also meets
the requirement of sufficient disclosure pursuant to Article 83.”29
Defining the essential features in the first-generation patent has an
impact on the assessment of novelty in the second-generation patent
application. The scientific disclosure is in direct conflict with the novelty
criteria but according to Art. 54 of the EPC, novelty is judged based on the
information made available at the time of the application. The novelty is thus
judged by the (scientific) knowledge available. The inventive step
requirement, on the other hand, refers to the enabling aspect of the invention
to be carried out by the person skilled in the art. or these reasons, the extent
of disclosure should be analyzed from two different angles, the scientific
disclosure, which is connected to the novelty, and the enabling aspect of the
disclosure, which is connected to the inventive step.

27. See European Patent Convention, supra note 22, art. 83.
28. European Patent Office, Guidelines for Examination, pt. F, ch. III, § 1 (2018),
https://www.epo.org/law-practice/legal-texts/html/guidelines/e/f_iii_1.htm.
29. Case T 198/84, Hoechst ex parte, OJ EPO (1985). In the EPO Case T 292/85 it was stated that
in certain cases a description of one way of performing the claimed invention might be sufficient to
support broad claims with functionally defined features. For example, where the disclosure of a new
technique constitutes the essence of the invention and the description of one way of carrying out the
invention enables the person skilled in the art to obtain the same effect of the invention in a broad area
by use of suitable variants of the component features. See Case T 0292/85, Genentech, OJ EPO (1988).
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In the case of prodrugs, although being structurally similar to the parent
drug, the main challenge does not arise from the scientific disclosure because
these types of inactive derivatives of original drugs usually contain improved
scientific knowledge. The inability to guarantee a patent for prodrugs stems
rather from the inability to come to terms with the practical aspect of the
disclosure because it raises questions whether a person skilled in the art was
expected to reach to a specific result already during the assessment of the
first-generation claim or not. Differently from prodrugs, the active
metabolites that are the molecules (end products) of a drug (or prodrug) are
generally considered as being already included in the first-generation claim
in Europe from both the scientific, as well as practical, point of view their
“behavior” during metabolism is a natural consequence, therefore they are
excluded from patentability. As a consequence, they do not fulfill even the
novelty requirement.
Still, under some circumstances, the scope of the patent is not limited
to the version that the inventor invented, but could cover the subsequently
modified versions if each falls within the scope.30 It can be deduced that the
inventor is not expected to include a “complete” scientific disclosure in the
patent application, but should provide sufficient information to the examiner
to carry out the invention. For some types of inventions, it can mean that the
disclosure, although sufficient from the practical point of view, may contain
“gaps” from the scientific aspect regarding any of its specific elements.
These elements, on the other hand, can themselves be patentable subject
matter, or may already be encompassed in the disclosure without being
directly referred. For example, prodrugs and especially metabolites thereof
can be viewed as anticipated inventions although they may not have been
previously disclosed in the parent claim. At the same time, prodrugs can be
viewed as a separate subject matter eligible for a new patent. The polemics
here is whether these second-generation prodrug claims should
automatically be refused to avoid a situation where the subject matter of the
first claim is indirectly encompassed in the second-generation claim or find
the prodrug patent valid which could mean that the first-generation invention
is delayed before entering the public domain. The extent of disclosure and
its effects on the novelty and inventive step requirements will be dealt with
in the following sections of this article.

30. Changing Patterns of Pharmaceutical Innovation, supra note 11, at 19.
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III. ASSESSMENT OF NOVELTY – THE MERRELL DOW CASE
Prodrugs are chemically modified versions of the pharmacologically
active agent that must transform in vivo to release the active drug. 31
Considering that claims involving prodrugs usually refer to minor
modifications of the structure or the chemical makeup of a molecule 32
meaning that they are only a few steps away from the parent drug, the main
challenge for patenting prodrugs as product related second-generation claims
comes from potential structural similarities to the parent drug of the firstgeneration claim. In other words, potential challenges arise from destroying
the novelty and/or inventive step requirements of Articles 54 and 56 of the
EPC. Article 54 requires that “for the invention to be considered novel, it
should not form part of the state of the art.”33 If the concept of an invention
is completely disclosed within a single piece of prior art, it lacks novelty,
regardless of whether it was independently developed from the earlier
invention.34 Thus, the novelty connects to the availability of already existing
information on prior art and the anticipation thereof. In case the invention is
already claimed in an earlier (first generation) invention, the prior disclosure
enables the entire claimed invention in addition to disclosing each and every
element of the invention. 35 According to John F. Duffy, 36 whether the
disclosure forms part of the state of the art depends whether there is a natural
result, meaning that it should be decided whether the later invention is the
natural result flowing explicitly from the earlier disclosure. What has to be
established in the examination as to novelty is whether the state of the art is
such as to make the subject matter of the invention available to the skilled
person in a technical teaching.37
In the case of prodrugs and active metabolites, the question that arises
is how to judge the extent of the scientific disclosure because this type of
second-generation inventions may already have been disclosed in the first
application without being disclosed. In other words, the question is how to

31. Id. at 2.
32. Case T 198/84, Hoechst ex parte, OJ EPO (1985) at 2–3.
33. See European Patent Convention, supra note 22, art. 54.
34. Stephen M. Mauer & Suzanne Scotchmer, The Independent-Invention Défense in Intellectual
Property, 69 ECONOMICA 535–47 (2002).
35. Synthon BV v. SmithKline Beecham plc [2005] H.L. 59, at ¶14.
36. See generally John F. Duffy, Rules and Standards on the Forefront of Patentability, 51 WM. &
MARY L. REV. 638, (2009).
37. Case T 198/84, ¶ 6, A generic disclosure does not destroy the novelty of any of the specific
possibilities falling within the disclosure unless it claims a specific generic feature that encompasses the
latter.
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define the extent of the disclosure for the assessment of novelty in the case
of prodrugs and metabolites thereof if they fall within a scientific “gap.” This
means that although they are not explicitly disclosed in the first-generation
application, they are nevertheless anticipated even when the inventor had no
knowledge about such an effect.
What has to be established in the examination as to novelty is whether
the state of the art is such as to make the subject matter of the invention
available to the skilled person in a technical teaching.38 However, different
from the evaluation over the inventive step is that compared and analyzed to
the existing technical criteria, novelty is evaluated not on what it adds to the
existing technical teaching, but whether it can be considered a new invention
overall. In other words, it is whether the subject matter of the invention is
available to the person skilled in the art in technical teaching, which thus
should be an absolute novelty, not a natural result of the existing disclosure.39
Differently, from assessing the inventive step, it is not the newly discovered
effect that is evaluated for novelty, but the new disclosure has to form a new
invention per se. For assessing novelty of second-generation claims, it is not
important whether there is a technical effect present over the prior art as this
is evaluated at the stage of analyzing the existence of the inventive step.
However, what is important about the technical teaching in the context of
novelty is that the second-generation patent should not disclose a teaching
that is anticipated by the examiner as a “natural result” of the first-generation
claim.
When the first-generation claim covering the parent drug already
included a possible (future) prodrug derivative, the novelty criteria in the
second-generation claim could not be met. The teaching of the prior art is
not confined to the detailed information given in the examples of how the
invention is carried out40 but relies on the information available in the claims
and the description of the application that becomes the starting point for the
person skilled in the art to carry out the invention and test novelty. For this
reason, according to the established EPO case law,
In the case of one of a number of chemical substances described by its
structural formula in a prior publication, that substance’s particular
stereospecific configuration (thereof form) - though not explicitly

38. Id. at ¶ 6.
39. The new disclosure should not be a mere embodiment of the prior disclosure but is expected to
form another invention. See Case T 0279/89, In re Texaco Dev. Corp., OJ EPO (1991) ¶ 4.1.
40. Case T 0012/81, In re Bayer AG, OJ EPO (1982).
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mentioned - is anticipated if it proves to be the inevitable but undetected
result of one of a number of processes adequately described in the prior
publication by indication of the starting compound and the process.41

Thus, when deducting this reasoning to prodrugs, if the second-generation
family of the compound partially already covered what was disclosed in the
first-generation disclosure, novelty cannot be approved. But at the same
time, “if the (second-generation) subject matter is a defined compound,
whereas the prior art discloses a family of [a] compound defined only by a
general formula covering the defined compound, but not describing it
explicitly, the invention must be considered novel.”42
Deducing from the EPO case law, the second-generation claim may
nevertheless fall within the scope of the parent claim, even if it was not
explicitly described as the disclosure of the parent claim that could already
anticipate the subject matter of the other claim due to the scientific “gap” or,
in other words, explicit anticipation. Therefore, the success of the secondgeneration patent application relies on available knowledge, the extent of
disclosure, and the wording of the patent application concerning what is
claimed.
The validity of prodrug and metabolite patents in Europe has been dealt
with in the landmark case Merrell Dow v. H.N. Norton & Co. Ltd. in the
UK43. The case concerned a metabolite of Terfenadine, which was a line
extension of the original drug patented in the 1970s. Considering that the
second-generation patent involving a metabolite was patented a decade later,
a generic drug company Norton challenged the metabolite patent as a de
facto extension of the original drug based on validity and/or infringement.
The case was under discussion in the U.S., Germany and the UK. In the first
two countries, the main challenge was about patent infringement whereas the
litigation brought up in the UK was the only country challenging the validity
of metabolite claims. Therefore, the questions regarding novelty and
inventive step arose in the context of challenging patent validity. Generally,
41. See supra, Section II.
42. The Board stated the following: “If a mere precisely structurally defined (described by a
chemical reaction) class of chemical compounds with only one generically defined substituent does not
represent a prior disclosure of all the theoretical compounds encompassed by an arbitrary choice of a
substituent definition, it must be clearly valid for a group of chemical substances, the general formula of
which has two variable groups. Therefore, in the present case, a class of chemical compounds, defined
only by a general structural formula having at least two variable groups does not specifically disclose
each of the individual compounds which would result from the combination of all possible variants within
such groups.” Case T 0007/86, DRACO v. Napp Labs. Ltd., OJ EPO (1987) ¶ 5.1.
43. Merrell Dow Pharms. Inc v. Norton & Co. Ltd., [1996] 3 RPC 76 , 87 (H.L.).
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for a patent in the second-generation application to be held invalid for the
lack of novelty, the prior art should disclose the same invention. In Merrell
Dow, Lord Hoffmann invalidated the patent for having been anticipated by
disclosure.44 The notion and extent of the disclosure were addressed in detail.
Referring to Art. 54 of the EPC, it was found that what constitutes
anticipation is not simply something that was done before.45 To determine
the extent of the disclosure and consequently, judge novelty, it should be
clarified what constitutes prior art in terms of “use” and (scientific) and
“disclosure.” Lord Hoffmann made a distinction between these terms as he
considered that for the prior art to have a destructive impact on the
assessment of novelty through use required that the information should have
been made public through its use which, in this specific case, was not an
issue. Instead, the judge found that the disclosure does not mean everything
made available to the public in a written form or by public statement. The
view was the disclosure by itself can contain information without being made
public through use, meaning that the result of the metabolite action in the
human body was due to the scientific disclosure (which was not, at the time,
known to the inventor) rather than due to the communication to the public
through its use. Thus, the second-generation invention should be anticipated
based on the (scientific) disclosure that enables a person skilled in the art to
convey sufficient information to work the invention.46 This means that the
anticipation by “use” has a different basis than anticipation by (scientific)
“disclosure”.
For purposes of clarifying the difference between these terms, Lord
Hoffmann stated the following referring to the CPC/Flour Concentrate
case47:
if the recipe which inevitably produces the substance is part of the state of
the art, so is the substance as made by the recipe. The prior inventor must
be clearly shown to have planted his flag at the precise destination before
the patentee.48

It seems what the judge had in mind is that when the subsequent
invention was performed based on the disclosure, it would necessarily have
led to the infringement of the initial patent. Thus, the outcomes of performing

44.
45.
46.
47.
48.

Merrell Dow Pharms. Inc v. Norton & Co. Ltd., [1996] 3 RPC 76 , 87 (H.L.).
Id. at 84.
Id. at 34
Id.
Id. at 90.
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the second-generation invention should not be one of the possible options or
result, but it should be based on the information disclosed even when it was
not explicitly described in the patent. It should be anticipated. If it is one of
the possible consequences, one cannot say that performing this invention
would infringe.49 This statement is supported by Union Carbide Corporation
v. Basf AG, Dow Chemical Co. and NV DSM. Here, the EPO Boards of
Appeal concluded that:
“[i]t may be easy, given a knowledge of a later invention, to select from
the general teachings of a prior art document certain conditions, and apply
them to an example in that document, so as to produce an end result having
all the features of the later claim. However, success in so doing does not
prove that the result was inevitable. All that it demonstrates is that, given
knowledge of the later invention, the earlier teaching is capable of being
adapted to give the same result. Such an adaptation cannot be used to
attack the novelty of a later patent.”50

In the case of metabolites that make an effect on the molecular level as
the end products after being metabolized, it is expected that when performing
the first-generation invention involving a drug it would necessarily result in
the same effects as the second-generation metabolites do. Therefore, the
result should be expected in the first-generation patent. Also, as discussed in
Merrell Dow, the (scientific) disclosure that sets the basis for the evaluation
of novelty may not be known to the inventor himself 51 Nevertheless, it does
not make the following claim valid. What matters is the disclosure must
necessarily result in an infringing invention in the second-generation claim
once performed. This is what sets novelty apart from the practical
enablement or in other words, inventive step requirement. In Merrell Dow,
the ingestion of terfenadine by hay-fever sufferers, which was the subject of
prior disclosure, necessarily entailed the making of the patented acid
metabolite in their livers. 52 It was, therefore, an anticipation of the acid
metabolite, even though no one was aware that it was being made or even
that it existed. A similar view regarding the assessment of novelty in light of
judging the extent of disclosure was seen in Synthon v. SmithKline Beecham
in the UK, which contested a patent for a crystalline form of paroxetine
49. Lord Hoffmann said, “. . . the prior disclosure must be construed as it would have been
understood by the skilled person at the date of the disclosure and not in the light of the subsequent patent.”
Id. at 84.
50. Case T 0396/89, Union Carbide Corp. v. BASF Aktiengesellschaft et al., OJ EPO (1991) ¶ 4.4
51. Synthon BV v. SmithKline Beecham plc [2005] H.L. 59, at 23.
52. Id. at 23.
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Methosulfate. 53 In Synthon, the judge sought to separate the notion of
disclosure from enablement since disclosure concerns novelty and
enablement concerns the obviousness/inventive step.54
As for assessing the novelty criteria in the light of prior disclosure, the
judge came to a similar conclusion as in Merrell Dow. The judge concluded
that relying on prior art should disclose the subject matter in a manner that,
if performed, it would necessarily result in patent infringement.55 Based on
these judgments, it can be concluded that for the assessment of novelty
concerning prodrugs and/or active metabolites the main doubt concerns the
extent of the scientific disclosure within the first-generation claim. In
evaluating disclosure, it does not matter whether the second-generation
subject matter was explicitly mentioned in the parent claim because, from
the scientific point of view, this type of subject matter is anticipated. The
existence and advantages of the second-generation subject matter are
generally, in this situation, disclosed because carrying out the invention
would inevitably lead to the production of the second-generation product by
the person skilled in the art. Although the concept of the invention is not
completely disclosed in the first claim, if the subject matter of the secondgeneration claim would fall within the scientific “gap” disclosed in the parent
drug, the result would inevitably lead to the construction and or effects of the
prodrug/metabolite claim. The Court interpreted the novelty provision to
find that the earlier patent had put information about the Terfenadine
metabolite into the public domain, despite not publicly teaching the ‘missing
element’ in the patent specification. 56 The findings and reasoning of the
decision in Merrell Dow are well-suited for justifying the inexistence of
novelty in the following patent application to avoid evergreening attempts as
part of drug life cycle management. Certainly, each case is judged based on
its contents, but the UK judgment has followed the same approach denying
metabolite patents in Europe as did the EPO. However, prodrugs are still
patentable subject matter in Europe as they are in the UK, but the passing of
the novelty test based on the contents of the disclosure depends on the
wording of a claim and the extent of the scientific disclosure. The following
section of the article discusses the understanding of disclosure within the

53. Id. at 23.
54. Id. at 66.
55. Id. at 22.
56. See generally H. Samuel Frost, The Unique Problem of Inventions which are Fully Enabled and
Fully Described but not Fully Understood(Merrell Dow’s Terfenadine Revisited), 15 INTELL. PROP. J.
2,(2007).

ASSESSMENT OF DISCLOSURE(DO NOT DELETE)

2019

ASSESSMENT OF DISCLOSURE IN EUROPEAN PRODRUG

5/20/2019 9:08 PM

443

notion of enablement as a means of assessing the inventive step in prodrug
and metabolite patent applications in Europe.
IV. DISCLOSURE AS AN ELEMENT OF ENABLEMENT FOR ASSESSING THE
INVENTIVE STEP

It has been an accepted legal principle that the extent of the patent
monopoly should correspond to and be justified by the technical contribution
to the state of art.57 Therefore, the extent to which an invention is sufficiently
disclosed as an element of enablement is highly relevant for the evaluation
of second-generation patent applications. The inventive step requirement is
considered the “final gatekeeper of the patent system.”58 This means that
even if relatively trivial changes to the prior art could survive the novelty
and industrial applicability requirements, the inventive step will function as
the ultimate requirement and filter the patentable from the unpatentable.59
The relevance of the inventive step requirement is to guarantee there is a
technical advancement in the teaching in comparison to the state of the art.
It should not be an extension or incremental development of technology,60
which may pass the novelty check but would add nothing to the level of
technological advancement.
The inventive step can only be assessed when the invention is deemed
novel. In comparison to the novelty, the inventive step seems to have higher
standards of applicability. Art. 56 of the EPC defines the inventive step in
the following manner: “An invention shall be considered as involving an
inventive step if, having regard to the state of the art, it is not obvious to a
person skilled in the art.”61 While both of these definitions deal with the state
of art the novelty criteria is informative. To pass the evaluation, the main
factor considered is the available information of prior art as discussed in the
previous section. Novelty is judged based on the scientific disclosure, which
may mean that this information can fall in the scientific “gap,” which
nevertheless can destroy novelty. The inventive step requirement, on the
other hand, refers to the technical teaching, which means in addition to being
novel to the examiner, the invention should contain a new technical

57. Case T 0409/91, In re Exxon Chem. Patents, Inc., (1993) at 3.3 (Eur. Pat. Bd. of App.).
58. R. P. MERGES & J. F. DUFFY, PATENT LAW AND POLICY: CASES AND MATERIALS 619–20
(LexisNexis, 5th ed. 2011).
59. Id. at 620.
60. Mark F. Grady & Jay L. Alexander, Patent Law and Rent Dissipation, 78 VA. L. REV. 305, 340
(1992).
61. See European Patent Convention, supra note 22, art. 56.
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contribution to the state of the art. While the novelty requirement puts the
examiner in a passive state,62 the inventive step requirement has the opposite
effect as it requires the active participation of the person skilled in the art to
perform tests and make the ultimate evaluation. The inventive step requires
that the invention, based on the prior art, is not obvious to the examiner. For
assessing the inventive step, the problem-solution approach is used. This
means that the second-generation claim should provide a technical problem
over the prior art that needs to be “solved” to see whether the solution can
be considered inventive (non-obvious) in comparison to the existing
knowledge. 63 Thus, an unexpected advantage that could not have been
predicted from the prior art is taken as evidence of an inventive step. In this
light, for the fulfillment of the inventive step requirement, the newly claimed
compound/molecule should present a special technical property that is not
previously disclosed. It means that the second-generation claim should offer
a “surprising” technical effect to the existing prior art. In the case of
prodrugs, it can be either a new property or a better activity in comparison
to the existing invention.
In the case of chemical inventions concerning potential structural
similarity, the EPO has taken the view64 that “to deny the patent for the lack
of the inventive step, a skilled person should be expected to find the same or
similar usefulness in comparison to the known compound as means of
overcoming the technical problem.” What makes the difference is the range
of structural differences of the second-generation drug when compared to the
parent compound. If these differences are lacking or very small, they would
have an insignificant bearing on those properties that are essential for solving
the technical problem at issue. Because of structural similarities with the
parent drug, the inventive step for a prodrug often turns on the structural
similarities and differences between the claimed compound and prior art.65
In T 2402/10 the board stated “in the field of drug design any structural
modification of a pharmacologically active compound is, in the absence of
an established correlation between structural features and activity, a priori

62. Id.; Frost, supra note 56, at 19.
63. In assessing the inventive step, the EPO has applied the following three-step test: “1.
Determining the ‘closest prior art’; 2. Establishing the ‘objective technical problem’ to be solved; and 3.
Considering whether or not the claimed invention, starting from the closest prior art and the objective
technical problem, would have been obvious to the skilled person.” See Implementing Regulations – to
the Convention on the Grant of European Patents of 5 October 1973.
64. Case T 0358/04, Retroviral protease inhibitors/G.D. SEARLE, OJ EPO (2006) ¶ 4.5.3 .
65. JARKKO RAUTIO, PRODRUGS AND TARGETED DELIVERY: TOWARDS BETTER ADME
PROPERTIES 73 (Wiley 2011).
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expected to disturb the pharmacological activity profile of the initial
structure.”66 In the case of prodrugs, the structural similarities in the firstand second-generation claims can otherwise lead to double patenting if the
inventive step is not approached with caution. Double patenting can be raised
where the subject matter of the granted invention is encompassed by the
claim later put forward.67 However, what makes the difference whether the
inventive step stage is passed successfully or not is whether the secondgeneration claim has distinguishing features in comparison to the firstgeneration claim. Under this condition, the subject matter of the secondgeneration claim and the first-generation claim cannot be considered as “the
same subject matter. Thus, the evaluation of the inventive step has stricter
standards in Europe when compared to the assessment of the novelty criteria.
The inventive step has to occur for the entire selection range, but the novelty
criteria is fulfilled when the claimed subject matter is distinguished from the
prior art in the range of overlap by a new technical element.68
As discussed in the previous section, to destroy novelty, the disclosure
must infringe the invention If the performance of an invention would make
the second-generation subject-matter obvious to the person skilled in the art
but not necessarily infringe the first one, then one can discuss the practical
enablement in judging the inventive step, not novelty. 69 Therefore, while
Merrell Dow divided the destruction of novelty into two categories, namely
disclosure by use and scientific disclosure, the inventive step requirement is
connected to the practical enablement of the disclosure. Enablement means
that a person skilled in the art should be able to perform the invention, which
satisfies the requirement of disclosure. 70 Thus, the inventive step can be
judged based on what is previously disclosed, meaning that for the
destruction of the inventive step, either the prior disclosure of the invention
or general common knowledge would have enabled a person skilled in the
art to make it.71 The inventive step depends on what is disclosed in the prior
art making it different from novelty, which may be judged, based on Merrell
Dow, also on the “missing” information (the scientific “gap”) in the
disclosure made available.
In Union/Carbide, the EPO Boards of Appeal clarified that:

66.
67.
68.
69.
70.
71.

Case T 2402/10, Prostaglandin derivatives / Pfizer, OJ EPO (2012).
Case T 0307/03, ARCO/Double patenting, [2007] (Eur. Tech. Bd. of App.).
Case T 0012/90, Bayer AG, OJ EPO (1990).
Id.; Synthon BV v. SmithKline Beecham plc [2005] H.L. 59, at 49.
Id.; Case T 0396/89, Union Carbide Corp. v. BASF Aktiengesellschaft et al., OJ EPO (1991).
Asahi Kasei Kogyo KK’s Application [1991] RPC 485 (HL).
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It may be easy, given a knowledge of a later invention, to select from the
general teachings of a prior art document certain conditions, and apply
them to an example in that document, so as to produce an end result having
all the features of the later claim. However, success in so doing does not
prove that the result was inevitable. All that it demonstrates is that, given
knowledge of the later invention, the earlier teaching is capable of being
adapted to give the same result. Such an adaptation cannot be used to
attack the novelty of a later patent. 72

If the disclosure of prior art would make it obvious to the skilled person how
to adapt the invention in a manner that could eventually result in
infringement, one can challenge the inventive step but not novelty because
the infringement would be based on the existing available information of
prior art. Secondly, enablement would not mean an automatic and inevitable
infringement, but it is one of the possibilities that may lead to such
infringement if adaptions are made. In other words, enablement means that
for the destruction of the inventive step, the skilled person is expected to
perform the invention, which satisfies the requirements of disclosure. Based
on Hill v. Evans,73 for the assessment of novelty, no further experiments with
the subject matter are performed as it is judged based on the (scientific)
disclosure. Given Merrell Dow, the argument in Union/Carbide and Hill v.
Evans is different because of the case’s substantial circumstances. Namely,
the intriguing aspect of Merrell Dow was that the second-generation
invention disclosed in the prior art was not the same as claimed in the
invention itself, but if performed by the examiner, it would infringe the
claimed invention. In this case, the debate concerned whether the disclosure
contained in the prior art enabled the examiner to make Terfenadine, not
whether it enabled him to make metabolites. This makes judging novelty
different from the inventive step and the questions that were raised regarding
validity in Merrell Dow concerned novelty, not the inventive step.

72. Id.; Case T 0396/89, Union Carbide Corporation v. BASF Aktiengesellschaft et al., OJ EPO
(1991) ¶ 4.4.
73. In Hill v. Evans in the UK, the House considered what would amount to disclosure of an
invention. Lord Westbury LC said “I apprehend the principle is correctly thus expressed: the antecedent
statement must be such that a person of ordinary knowledge of the subject would at once perceive,
understand and be able practically to apply the discovery without the necessity of making further
experiments and gaining further information before the invention can be made useful. If something
remains to be ascertained which is necessary for the useful application of the discovery, that affords
sufficient room for another valid patent.” Hill v. Evans, (1862) 31 LJ (NS) 457, 463.
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CONCLUDING REMARKS
Although second-generation patents are sometimes seen as lacking true
inventiveness and, therefore, should perhaps not be granted,74 it is not always
the case. The main concern about drug patent has been the issuing of
secondary patents with questionable value, meaning that although a patent
can qualify from the technical point of view for a new patent but it may not
necessarily have any significant therapeutic value from the medical aspect.
It has therefore been questioned whether these types of patents rather reflect
their input and true innovative value. Lemley and Shapiro have pointed out
that among the vast number of patents filed most of them have little value
and such patenting leads to a situation where third parties have no
meaningful opportunity to participate in the patent granting system. 75
Burdon and Sloper state that “[a] key element of any lifecycle management
strategy is to extend patent protection beyond the basic patent term for as
long as possible by filing secondary patents, which are effective at keeping
generics off the market.”76 According to the Pharmaceutical Sector Inquiry,
which studied the tendencies of European pharmaceutical companies to use
sequential patents, the primary-to-secondary patent ratio is 1:7, and
interestingly, the ratio for pending patents is much higher in comparison to
granted patents.77 Another study conducted in the U.S. market suggested that
around half of pharmaceutical products are additionally covered with followon patents.78
Lemley and Shapiro79 argue that “[m]odern technologies incorporate
not one but a number of combinations of patents for different components of
the basic invention.” A study conducted by Stella has suggested that, in many
cases, a look at the structure of the active drug with the additional claim of
prodrugs suggested that prodrugs would serve minimal advantage. 80
According to his estimation, the vast majority of prodrug patents contain
74. Id.; Asahi Kasei Kogyo KK’s Application [1991] RPC 485 (HL).
75. See generally Mark A. Lemley & Carl Shapiro, Probabilistic patents, 19 J. ECON. PERSP. 75
(2005).
76. Michael Burdon & Kristie Sloper, The Art of Using Burden Secondary Patents to Improve
Protection, 3 INT’L J. MED. MARKETING, 226, 266 (2003).
77. EUROPEAN COMM’N, PHARMACEUTICAL SECTOR INQUIRY REPORT (2009),
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf.
78. See generally Amy Kapczynski et al., Polymorphs and Prodrugs and Salts (Oh My!): An
Empirical Analysis of “‘Secondary” Pharmaceutical Patents, 7 PLOS ONE 49470 (2012).
79. See generally Mark A. Lemley & Carl Shapiro, Patent Holdup and Royalty Stacking, 85 TEX.
L. REV. 1992 (2007).
80. See generally Valentino J. Stella, Prodrugs: Some thoughts and current issues, 99 J. PHARM.
SCI. 4755 (2010).
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little true novelty either in the chemical or biological sense meaning that less
than 5-10 percent of the patents represent true creativity. 81 Correa has made
a similar conclusion arguing that “[a] claim on a prodrug will generally fail
to meet the inventive step standard unless evidence is provided that it
overcomes pharmaceutical or pharmacokinetically based problems of the
parent drug in a non-evident manner.”82
Although the improved efficacy of prodrugs in overcoming the barriers
in parent drug delivery can be disputed, the standards applicable to these bioreversible derivatives of drug molecules consider the technical side of
claimed inventions. A key consideration under patent law is whether the
development of a new prodrug is the outcome of an inventive activity or of
routine research and experimentation. The first question that was addressed
in these article was the extent of disclosure in second-generation patent
applications concerning prodrugs. The second question, which is closely
connected to the first one, is the validity of the prodrug patents in the light
of fulfillment of novelty and inventive step requirements. To analyze these
issues, this article provided an overview about the scientific notion of
prodrugs and active metabolites explaining that because of structural
similarities with the parent drug, prodrugs and active metabolites face
challenges in overcoming the patentability criteria pertaining in the
European Patent Convention. This article further analyzed the understanding
of the term “disclosure” in European patent applications arguing that the
scientific disclosure should be separated from the practical disclosure as they
are targeted to judging different criteria of patentability. The extent of
disclosure has a direct impact on the assessment of novelty and the inventive
step requirements in European patent application. As analyzed in Merrell
Dow the scientific disclosure relates to the novelty criteria. Deduced from
the analysis in Merrell Dow, it was concluded that although novelty is
generally assessed based on the information made available to the public, in
cases involving subject matter targeting prodrugs and metabolites, it is
possible that the scientific disclosure that sets the basis for the assessment of
novelty, falls within the scientific “gap” meaning that it may not even be
communicated to the public to be considered as prior art. Thus, although
novelty contains the element of anticipation, one should distinguish between
anticipation by “use” and by (scientific) “disclosure.” When this discussion
is applied to the assessment of novelty for prodrugs and metabolite patents,
81. Id. at 4755.
82. Carlos M. Correa, Guidelines for Pharmaceutical Patent Applications: Examining
Pharmaceutical Patents from Public Health Perspective, UNDP, at 10 (2015),
https://www.undp.org/content/dam/undp/library/HIV-AIDS/UNDP_patents_final_web_2.pdf.
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the disclosure, even if not directly stated in the application of the parent drug,
would inevitably infringe that patent if the second invention was performed.
Thus, the prodrug/metabolite should (from the scientific perspective) be
expected to contain the parent drug already.
The article also dealt with the legal analysis concerning the assessment
of the inventive step arguing that the disclosure should be based strictly on
the information made available the prior art. Differently, from the scientific
disclosure that is a passive notion, the disclosure involving enablement
requires active performance from the examiner to conduct tests with the
subject matter. To destroy the inventive step requirement, enablement should
be based on the information available in the prior art and the examiner should
be capable of performing the invention as disclosed.

